Contact

info@syndevrx.com

1 Broadway # 14, Cambridge, MA 02142

Effects of Diet and Exercise induced Weight Loss on Biomarkers of Inflammation in Breast Cancer Survivors

Leptin may be a primary mediator of exercise-induced improvements in breast cancer recurrence.

Read More

Type 2 diabetes and cancer: an umbrella review of observational and Mendelian randomisation studies

The opportunity to draw upon genetic data from large-scale, international consortia allows for triangulation of evidence using distinct methodological approaches that make orthogonal underlying assumptions and suffer from distinct sources of bias. The findings of our study support a potential causal effect of genetically predicted T2DM and/or fasting insulin levels, rather than genetically predicted fasting […]

Read More

Could metabo-oncology be the treatment modality of the future?

Jim Shanahan from SynDevRx explains why metabo-oncology treatment modalities could be the answer to a rise in metabolic disorders and cancers.

Read More

SynDevRx Assembles Prostate Cancer Medical Advisory Board to Oversee Drug Candidate That Targets Link Between Obesity and Prostate Cancer

SynDevRx, Inc., a clinical-stage biopharmaceutical company specializing in metabo-oncology, has announced the formation of its Prostate Cancer Medical Advisory Board (PCMAB), comprised of key opinion leaders and industry experts in clinical oncology research and prostate cancer patient care. The board’s overarching goal is to inform the development of SynDevRx’s lead drug candidate, SDX-7320, to target […]

Read More

Are Metabolic Hormones the Next Frontier in Cancer Treatment?

With a global epidemic of obesity and diabetes and their known relationship to cancer, researchers and oncologists are turning their attention to metabolic hormones as promising new targets for cancer treatment.

Read More

The Link Between Cancer and Metabolic Dysfunction

Technology Networks recently spoke with Jim Shanahan, co-founder, chief business officer and director of SynDevRx, to explore the impact of metabolic dysfunction on treatment outcomes and learn more about the company’s lead compound SDX-7320.

Read More

SynDevRx Announces Positive Data from Phase 1 Safety Trial of SDX-7320 in Late Stage Cancer Patients

SynDevRx, Inc., a clinical-stage oncology company, has submitted results of its Phase 1 dose escalation safety study in late-stage cancer patients with progressive, metastatic solid tumors to the United States Food and Drug Administration (FDA). The study’s primary endpoint was to establish the maximum tolerated dose and dosing schedule and the recommended Phase 2 dose […]

Read More

SynDevRx Clinical Drug Candidate SDX-7320 Offsets Hyperglycemia Caused by PI3K/Akt/mTOR Cancer Therapies and Restores Insulin Sensitivity, Preclinical Studies Show

SynDevRx, Inc., a clinical-stage oncology company, announces the completion of a series of preclinical studies demonstrating that its anti-cancer drug candidate, SDX-7320, inhibits PI3K/Akt inhibitor-induced hyperglycemia and subsequent hyperinsulinemia in normal mice and inhibits tumor growth in multiple models of HR+ breast cancer. The company’s ongoing research places them at the vanguard of metabo-oncology, an emerging field of cancer research that focuses on the role metabolic hormones play in the development and progression of many common cancers, as well as tumor resistance developed in response to certain treatment.

Read More

Co-Founder and Chief Business Officer James Shanahan Discusses Metabo-Oncology and Breast Cancer

Read More

AACR 2020: SynDevRx Selected to Present the Results from its Phase 1 Study of SDX-7320 in Late-Stage Cancer Patients

SynDevRx recently completed a Phase 1 study in late-stage cancer patients with a variety of solid tumors. The initial results from the clinical study were selected by AACR for presentation by one of the Principle Investigators – Dr. Monica Mita, MD. Dr. Mita is a Professor of Medicine, Co-Director, Experimental Therapeutics Program at Cedars-Sinai Medical […]

Read More